Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLWAVE-011: Nemtabrutinib vs Ibrutinib or Acalabrutinib in Untreated CLL/SLL
2022-501697-19-01Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised trial of nemtabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 arms), sponsored by Merck & Co. Primary endpoints: Objective Response Rate (ORR) and Progression-Free Survival (PFS). Planned start Jun 2024; status: authorised.
02
Drugs
nemtabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2022-501697-19-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501697-19-01.